Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 51: 681-683, 2005; 10.1373/clinchem.2004.047431
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sacks, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sacks, D. B.
Related Collections
Right arrow Current Issues in Laboratory Medicine
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2005;51:681-683.)
© 2005 American Association for Clinical Chemistry, Inc.


News

Global Harmonization of Hemoglobin A1c

David B. Sacks for the ADA/EASD/IDF Working Group of the HbA1c Assay

Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, 75 Francis St., Thorn 530, Boston, MA 02115, Fax 617-278-6921,

E-mail dsacks@rics.bwh.harvard.edu

The first 300 words of the full text of this article appear below.

Measurement of glycohemoglobin (GHb) is widely used in patients with diabetes mellitus as a monitor of long-term glycemic control (1)(2)(3). In addition, prospective randomized clinical trials, most notably the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), have demonstrated that GHb is a measure of the risk for the development of diabetes complications (4)(5). GHb is therefore an integral component of the management of patients with diabetes.

GHb comprises several different hemoglobin-glucose adducts, including hemoglobin A1a (HbA1a), HbA1b, and HbA1c. More than 30 different methods are commercially available to measure GHb. Together these factors have led to considerable variation in reference intervals and results reported by different laboratories. When the DCCT was published in 1993, the lack of standardization of GHb methods produced very wide variability among methods, with values ranging from 4.0% to 8.1% on the same blood sample (6). In the United States, the NGSP (previously known as the National Glycohemoglobin Standardization Program) has reduced interlaboratory variation (7). Using a standardization process based on the DCCT reference method, the NGSP has promoted a dramatic improvement in comparability of GHb values among laboratories (3). Data from the 2003 GH2 survey from the College of American Pathologists indicated that ≥98% of participating laboratories use NGSP-certified methods and report results as HbA1c or HbA1c equivalents (3). Analogous standardization programs in Sweden and Japan (8)(9), established to harmonize GHb results, have also reduced variability among GHb results. More recently, the IFCC Working Group on HbA1c Standardization prepared primary reference materials of pure HbA1c and HbA0 and developed a reference method for HbA1c (10). They defined HbA1c as the stable adduct of glucose . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
Ann Clin BiochemHome page
N. Iqbal, C. Morgan, H. Maksoud, and I. Idris
Improving patients' knowledge on the relationship between HbA1c and mean plasma glucose improves glycaemic control among persons with poorly controlled diabetes
Ann Clin Biochem, September 1, 2008; 45(5): 504 - 507.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
A H Berg and D B Sacks
Haemoglobin A1c analysis in the management of patients with diabetes: from chaos to harmony
J. Clin. Pathol., September 1, 2008; 61(9): 983 - 987.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
D. M. Nathan, J. Kuenen, R. Borg, H. Zheng, D. Schoenfeld, R. J. Heine, and for the A1c-Derived Average Glucose (ADAG) Study G
Translating the A1C Assay Into Estimated Average Glucose Values
Diabetes Care, August 1, 2008; 31(8): 1473 - 1478.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. D. Saudek, W. H. Herman, D. B. Sacks, R. M. Bergenstal, D. Edelman, and M. B. Davidson
A New Look at Screening and Diagnosing Diabetes Mellitus
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2447 - 2453.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
E. S. Kilpatrick, A. S. Rigby, and S. L. Atkin
Variability in the Relationship between Mean Plasma Glucose and HbA1c: Implications for the Assessment of Glycemic Control
Clin. Chem., May 1, 2007; 53(5): 897 - 901.
[Abstract] [Full Text] [PDF]


Home page
DOC NewsHome page
S. Kreimer
Inflammation Raises Risk of Diabetes, CVD
DOC News, April 1, 2007; 4(4): 8 - 8.
[Full Text]


Home page
Clin. Chem.Home page
G. L. Hortin
A New Era in Protein Quantification in Clinical Laboratories: Application of Liquid Chromatography-Tandem Mass Spectrometry
Clin. Chem., April 1, 2007; 53(4): 543 - 544.
[Full Text] [PDF]


Home page
JAMAHome page
C. D. Saudek, R. L. Derr, and R. R. Kalyani
Assessing Glycemia in Diabetes Using Self-monitoring Blood Glucose and Hemoglobin A1c
JAMA, April 12, 2006; 295(14): 1688 - 1697.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

An opinion on a news item
Trefor N Higgins
Clinical Chemistry Online, 4 May 2005 [Full text]



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.